A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 May 2017

At a glance

  • Drugs Demcizumab (Primary) ; Carboplatin; Pembrolizumab; Pemetrexed
  • Indications Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 08 May 2017 According to a company media release, OncoMed is discontinuing the dosing of all patients on the demcizumab trials and will conduct a complete program review in the near term with its partner Celgene.
    • 08 May 2017 Status changed from active, no longer recruiting to discontinued, according to an OncoMed Pharmaceuticals media release.
    • 13 Apr 2017 According to an OncoMed Pharmaceuticals media release, company will discontinue any enrollment in ongoing demcizumab trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top